Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04635735 · ClinicalTrials.gov registry record · Phase 1
Study of Ipilimumab After Stem Cell Transplantation in People With Relapsed/Refractory Multiple Myeloma
A Phase 1 study, sponsored by Memorial Sloan Kettering Cancer Center.
- Terminated
- Registry status
- Phase 1
- Development phase
- 3
- Enrollment target
NCT04635735: Clinical Trial Phase 1 study, sponsored by Memorial Sloan Kettering Cancer Center.
NCT04635735 is a Phase 1 study that was terminated before completion, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 3 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04635735, a Phase 1 study, was terminated before completion, sponsored by Memorial Sloan Kettering Cancer Center.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 3 participants
- Enrollment target
Study Summary
This study will test the safety of ipilimumab to see what effects, if any, the drug has when used as maintenance therapy for people with relapsed/refractory multiple myeloma who have received chemotherapy and allogeneic hematopoietic stem cell transplant (AHCT). The investigators also want to find out whether giving ipilimumab after chemotherapy and AHCT is a better way to control the multiple myeloma than chemotherapy and AHCT alone.
Interventions
- DRUG Ipilimumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3 participants |
| Start Date | 2020-01-12 |
| Est. Completion | 2023-02-02 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04635735
The ClinicalTrials.gov registry entry for NCT04635735 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 3 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Memorial Sloan Kettering Cancer Center, which has 1,884 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Ipilimumab is the first listed.
NCT04635735 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04635735 about?
NCT04635735 is a clinical study titled "Study of Ipilimumab After Stem Cell Transplantation in People With Relapsed/Refractory Multiple Myeloma". This study will test the safety of ipilimumab to see what effects, if any, the drug has when used as maintenance therapy for people with relapsed/refractory multiple myeloma who have received chemotherapy and allogeneic hematopoietic stem cell transplant (AHCT). The investigators also want to find o...
What is the current status of trial NCT04635735?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 3 participants. The study started on 2020-01-12. Estimated completion is 2023-02-02.
What interventions are being tested in trial NCT04635735?
The interventions under investigation include: Ipilimumab (DRUG).
Who is sponsoring clinical trial NCT04635735?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.